The Importance of the Analytical Evaluation Threshold (AET) in Extractable and Leachable Studies
The Analytical Evaluation Threshold (AET) is critical in developing your analytical approaches to identifying and quantifying extractables and leachables (E&L). This mathematical calculation is used to convert a dose-based threshold to a concentration-based threshold, which the analytical chemist then uses, to ensure that the analytical methods employed meet the required levels of sensitivity.
What is the AET Analytical Evaluation Threshold?
The AET concept was originally developed by the PQRI best practices group working on the ‘safety thresholds and best practices for E&L in orally inhaled and nasal drug products’ guideline (2006).
It is important to stress that the AET is not a safety threshold but an identification threshold used by the analytical chemist, once an extractable or leachable has been identified and quantified a toxicologist can assess whether that particular species represents a risk to the patient at the quantified an exposure level for the particular detected extractable/leachable.
The sensitivity of the detector to a given analyte is fixed. Working within the constraints of the detector’s sensitivity and the dose-based threshold there are a number of variables that can be used by the analytical chemist, when designing the extraction study, to ensure the AET is greater than the method’s limit of detection. Below provides a high-level schematic of these considerations.
The AET calculation
In order, to explore the variables that can be manipulated, to help ensure the AET is greater than the methods LOQ, it is worth reviewing an example AET calculation for medical devices.
DBT = Dose-Based Threshold (DBT) = Threshold of Toxicological Concern (TTC) as per ICH M7 or
A = number of medical devices extracted
B = extract volume
C = number of medical devices that contact the body/day
CF = extract concentration factor
UF = analytical methods uncertainty factor
S= number of sequential extractions (as per 10993-18 exhaustive extraction)
The variables that an analytical chemist can manage to ensure that the AET is greater than an instruments LOQ include:
- Minimizing the solvent volume to sample ratio
- Performing an extract concentration step to increase the analyte concentration. Note: care should be taken to not lose analytes
- Increase the amount of extract that is loaded onto the analytical equipment
Calculating the appropriate AET can be further complicated depending on the test items use and application, defining the appropriate AET is therefore, a collaborative calculation between the analytical chemist and individuals who have knowledge on the clinical use of the product.
The following example highlights how the different use cases can impact the AET for a product which is dosed, to a patient, twice daily from a device which contains 1 dose.
Depending on the devices application the AET can be vastly different depending on whether it is considered a medical device or medicinal product.
This is because the approaches to the extraction may differ between ISO 10993-18 and USP 1663, there are differences in historically accepted SCT/DBTs, and because different regulatory bodies have historically accepted different values for the uncertainty factor.
In the example factors such as the extraction volume and number of devices extracted were kept the same.
Note: the values given in this example are for demonstration purposes only and should not be taken as values that would be accepted by regulatory authorities.
Whilst there is a large variability in the final AET values it is worth noting that a concentration step, in order to ensure the AET > LOQ, would likely only be required for the final example.
In summary
The AET is a very important concept in extractable and leachable testing and is key in designing and developing these studies. Depending on the use and application of the device the values used to calculate the AET can differ. It is also important to remember that the AET must be above the limit of detection of the given method.
Find out more about our extrables and leachables services.
Find related Resources
Extractables & Leachables Studies
ºÚÁϲ»´òìÈ has one of the largest and most experienced extractables and leachables (E&L) practices in the world.
Backed by regulatory expertise, extensive experience, and a vast extractables database, our comprehensive E&L solutions ensure the safety of materials used across the healthcare sector.
We deliver tailored studies for pharmaceutical, biologic, medical device, reduced risk, combination products and more, in accordance with regulatory expectations.
READ MORERelated Resources
Related Pages
Extractables and Leachables Studies
ºÚÁϲ»´òìÈ's extractables and leachables studies offer tailored solutions that ensure patient safety and compliance with industry standards.
Medical Device Testing
As a comprehensive testing partner, you’ll enjoy the benefit of a single supplier source for all of your testing needs, from mechanical testing and environmental simulation to EMC and wireless device testing.
Pharmaceutical Testing
ºÚÁϲ»´òìÈ’s pharmaceutical laboratories provide specialist pharmaceutical testing services, including chemical, physical, microbial, and stability testing on a vast array of products, from raw materials to finished products.
USP 665, 1665 and BPOG Services
Ensure compliance for single-use systems (SUS). Our testing services provide high-quality results, safeguarding patient safety, fulfilling your regulatory requirements, and expediting time to market.
Excipient Raw Materials and Container Testing
Find out how we make certain that quality and safety of your excipient raw materials and containers are maintained.
Chemistry, Manufacturing, and Controls (CMC) Consulting Services
We provide consulting services for Chemistry, Manufacturing, and Controls (CMC) product development in the pharmaceutical and biotechnological industries.
ICH Stability Testing of Pharmaceuticals and Biologics
We'll help you develop comprehensive stability programs that meet ICH Q1A-F requirements for IND, ANDA, and NDA approvals of small and large molecule drugs.Â